Do analysts prefer ZSQR or IMUX?

Immunic has a consensus target price of $47.57, suggesting a potential upside of 216.09%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immunic 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.00

Is ZVRA or IMUX more profitable?

Zevra Therapeutics has a net margin of 101.58% compared to Immunic's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Zevra Therapeutics 101.58% 51.49% 28.86% Immunic N/A -220.75% -132.04%

Which has higher earnings and valuation, CYRX or IMUX?

CryoPort has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.25 $78.30M $1.35 11.02 Immunic N/A N/A -$97.17M -$5.58 N/A

Is CYRX or IMUX more profitable?

CryoPort has a net margin of 41.57% compared to Immunic's net margin of 0.00%. CryoPort's return on equity of -7.92% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort 41.57% -7.92% -4.79% Immunic N/A -220.75% -132.04%

Which has higher earnings and valuation, IVA or IMUX?

Immunic has lower revenue, but higher earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $4.48M 167.03 -$400.67M N/A N/A Immunic N/A N/A -$97.17M -$5.58 N/A

Is IVA or IMUX more profitable?

Inventiva's return on equity of 0.00% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Immunic N/A -220.75% -132.04%

Is ALLO or IMUX more profitable?

Allogene Therapeutics' return on equity of -56.45% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Immunic N/A -220.75% -132.04%

Immunic (IMUX) Competitors

$15.05 -0.02 (-0.13%)

As of 10:07 AM Eastern

Compare

IMUX vs. ZSQR, ZVRA, CYRX, IVA, and ALLO

Should you buy Immunic stock or one of its competitors? MarketBeat compares Immunic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunic include Coeptis Therapeutics (ZSQR), Zevra Therapeutics (ZVRA), CryoPort (CYRX), Inventiva (IVA), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry.

How does Immunic compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Immunic has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Coeptis Therapeutics' return on equity of -92.29% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Immunic	N/A	-220.75%	-132.04%

Coeptis Therapeutics has a beta of -0.22, suggesting that its share price is 122% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Coeptis Therapeutics has higher revenue and earnings than Immunic. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	497.28	-$11.92M	-$2.52	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Immunic has a consensus target price of $47.57, suggesting a potential upside of 216.09%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Coeptis Therapeutics' average media sentiment score of 0.00 equaled Immunic'saverage media sentiment score.

Company	Overall Sentiment
Coeptis Therapeutics	Neutral
Immunic	Neutral

Summary

Immunic beats Coeptis Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Immunic compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Zevra Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Zevra Therapeutics presently has a consensus price target of $29.29, indicating a potential upside of 122.01%. Immunic has a consensus price target of $47.57, indicating a potential upside of 216.09%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Zevra Therapeutics has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	6.38	$83.23M	$1.99	6.63
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

In the previous week, Zevra Therapeutics had 2 more articles in the media than Immunic. MarketBeat recorded 2 mentions for Zevra Therapeutics and 0 mentions for Immunic. Zevra Therapeutics' average media sentiment score of 0.00 equaled Immunic'saverage media sentiment score.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Immunic	Neutral

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zevra Therapeutics has a net margin of 101.58% compared to Immunic's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Immunic	N/A	-220.75%	-132.04%

Summary

Zevra Therapeutics beats Immunic on 9 of the 15 factors compared between the two stocks.

How does Immunic compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Immunic (NASDAQ:IMUX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

CryoPort has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, Immunic has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

CryoPort presently has a consensus target price of $15.11, suggesting a potential upside of 1.61%. Immunic has a consensus target price of $47.57, suggesting a potential upside of 216.09%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

CryoPort has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.25	$78.30M	$1.35	11.02
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

In the previous week, CryoPort had 1 more articles in the media than Immunic. MarketBeat recorded 1 mentions for CryoPort and 0 mentions for Immunic. CryoPort's average media sentiment score of 1.67 beat Immunic's score of 0.00 indicating that CryoPort is being referred to more favorably in the media.

Company	Overall Sentiment
CryoPort	Very Positive
Immunic	Neutral

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 10.1% of CryoPort shares are owned by company insiders. Comparatively, 5.5% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CryoPort has a net margin of 41.57% compared to Immunic's net margin of 0.00%. CryoPort's return on equity of -7.92% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Immunic	N/A	-220.75%	-132.04%

Summary

CryoPort beats Immunic on 13 of the 16 factors compared between the two stocks.

How does Immunic compare to Inventiva?

Inventiva (NASDAQ:IVA) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Inventiva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Inventiva's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Immunic	N/A	-220.75%	-132.04%

Immunic has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$4.48M	167.03	-$400.67M	N/A	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

In the previous week, Inventiva had 1 more articles in the media than Immunic. MarketBeat recorded 1 mentions for Inventiva and 0 mentions for Immunic. Inventiva's average media sentiment score of 0.00 equaled Immunic'saverage media sentiment score.

Company	Overall Sentiment
Inventiva	Neutral
Immunic	Neutral

Inventiva presently has a consensus target price of $16.56, suggesting a potential upside of 359.24%. Immunic has a consensus target price of $47.57, suggesting a potential upside of 216.09%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts plainly believe Inventiva is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 5.5% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Inventiva beats Immunic on 7 of the 10 factors compared between the two stocks.

How does Immunic compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Allogene Therapeutics' return on equity of -56.45% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Immunic	N/A	-220.75%	-132.04%

Allogene Therapeutics currently has a consensus price target of $8.52, indicating a potential upside of 307.18%. Immunic has a consensus price target of $47.57, indicating a potential upside of 216.09%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Allogene Therapeutics had 1 more articles in the media than Immunic. MarketBeat recorded 1 mentions for Allogene Therapeutics and 0 mentions for Immunic. Immunic's average media sentiment score of 0.00 beat Allogene Therapeutics' score of -1.74 indicating that Immunic is being referred to more favorably in the news media.

Company	Overall Sentiment
Allogene Therapeutics	Very Negative
Immunic	Neutral

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 5.5% of Immunic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immunic has lower revenue, but higher earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	36,119.95	-$190.89M	-$0.77	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

Summary

Allogene Therapeutics beats Immunic on 9 of the 15 factors compared between the two stocks.

Get Immunic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMUX vs. The Competition

Export

Metric	Immunic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$204.98M	$3.52B	$6.58B	$12.14B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-2.70	20.35	24.81	24.06
Price / Sales	N/A	331.06	552.47	123.81
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	-27.36	8.36	10.77	6.51
Net Income	-$97.17M	$23.85M	$3.56B	$337.03M
7 Day Performance	5.99%	4.10%	1.97%	0.10%
1 Month Performance	15.33%	3.45%	1.45%	1.07%
1 Year Performance	112.57%	57.16%	31.07%	28.66%

Immunic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMUX Immunic	2.501 of 5 stars	$15.05 -0.1%	$47.57 +216.1%	+112.9%	$204.98M	N/A	N/A	70
ZSQR Coeptis Therapeutics	0.1628 of 5 stars	$14.71 -12.1%	N/A	+89.8%	$756.55M	N/A	N/A	2	Gap Down High Trading Volume
ZVRA Zevra Therapeutics	4.0524 of 5 stars	$12.65 -1.9%	$29.29 +131.5%	+44.4%	$747.87M	$106.47M	6.36	20	Analyst Forecast
CYRX CryoPort	2.8219 of 5 stars	$14.77 -1.6%	$15.11 +2.3%	+125.0%	$744.41M	$176.18M	10.94	1,186	News Coverage Positive News
IVA Inventiva	1.9783 of 5 stars	$3.51 -1.7%	$16.56 +371.7%	+11.1%	$729.06M	$5.07M	N/A	100	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMUX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunic (IMUX) Competitors

IMUX vs. ZSQR, ZVRA, CYRX, IVA, and ALLO

How does Immunic compare to Coeptis Therapeutics?

Summary

How does Immunic compare to Zevra Therapeutics?

Summary

How does Immunic compare to CryoPort?

Summary

How does Immunic compare to Inventiva?

Summary

How does Immunic compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunic (IMUX) Competitors

IMUX vs. ZSQR, ZVRA, CYRX, IVA, and ALLO

How does Immunic compare to Coeptis Therapeutics?

Is ZSQR or IMUX more profitable?

Which has more risk & volatility, ZSQR or IMUX?

Do insiders and institutionals hold more shares of ZSQR or IMUX?

Which has better earnings and valuation, ZSQR or IMUX?

Do analysts prefer ZSQR or IMUX?

Does the media favor ZSQR or IMUX?

Summary

How does Immunic compare to Zevra Therapeutics?

Which has more volatility and risk, ZVRA or IMUX?

Do analysts recommend ZVRA or IMUX?

Which has preferable valuation & earnings, ZVRA or IMUX?

Does the media refer more to ZVRA or IMUX?

Do institutionals & insiders believe in ZVRA or IMUX?

Is ZVRA or IMUX more profitable?

Summary

How does Immunic compare to CryoPort?

Which has more risk & volatility, CYRX or IMUX?

Do analysts recommend CYRX or IMUX?

Which has higher earnings and valuation, CYRX or IMUX?

Does the media favor CYRX or IMUX?

Do institutionals and insiders hold more shares of CYRX or IMUX?

Is CYRX or IMUX more profitable?

Summary

How does Immunic compare to Inventiva?

Which has more risk & volatility, IVA or IMUX?

Is IVA or IMUX more profitable?

Which has higher earnings and valuation, IVA or IMUX?

Does the media favor IVA or IMUX?

Do analysts recommend IVA or IMUX?

Do institutionals and insiders hold more shares of IVA or IMUX?

Summary

How does Immunic compare to Allogene Therapeutics?

Is ALLO or IMUX more profitable?

Do analysts rate ALLO or IMUX?

Does the media favor ALLO or IMUX?

Do institutionals and insiders believe in ALLO or IMUX?

Which has stronger earnings & valuation, ALLO or IMUX?

Which has more risk and volatility, ALLO or IMUX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools